针对 NKG2A 设陷阱，让 NK 细胞免疫疗法有一线生机。
Setting traps for NKG2A gives NK cell immunotherapy a fighting chance.
出版信息
J Clin Invest. 2019 Apr 15;129(5):1839-1841. doi: 10.1172/JCI128480.
Abstract
The equilibrium of signaling through activating and inhibitory receptors dictates whether a given NK cell will execute cellular cytotoxicity. In this issue of the JCI, Kamiya et al. describe a novel approach to efficiently inhibiting surface expression of the inhibitory receptor CD94/NK group 2 member A (NKG2A) through retention of the protein in the endoplasmic reticulum. In adoptive transfer experiments into tumor-bearing immunodeficient mice, NKG2Anull NK cells were significantly more effective at eliminating HLA-E-expressing tumor cells than NKG2A+ NK cells. This study provides proof of concept for a new immunotherapeutic approach using NKG2Anull NK cells.
摘要
激活和抑制性受体的信号平衡决定了给定的 NK 细胞是否会执行细胞毒性。在本期 JCI 中，Kamiya 等人描述了一种通过将蛋白质保留在内质网中从而有效抑制抑制性受体 CD94/NK 组 2 成员 A（NKG2A）表面表达的新方法。在过继转移实验中，将 NKG2A 缺失的 NK 细胞输入到荷瘤免疫缺陷小鼠中，与 NKG2A+ NK 细胞相比，它们更有效地消除 HLA-E 表达的肿瘤细胞。这项研究为使用 NKG2A 缺失的 NK 细胞的新免疫治疗方法提供了概念验证。
相似文献
1
Setting traps for NKG2A gives NK cell immunotherapy a fighting chance.针对 NKG2A 设陷阱，让 NK 细胞免疫疗法有一线生机。
J Clin Invest. 2019 Apr 15;129(5):1839-1841. doi: 10.1172/JCI128480.
2
Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells.阻断抑制性受体 NKG2A 的表达可克服肿瘤对 NK 细胞的抵抗。
J Clin Invest. 2019 Mar 12;129(5):2094-2106. doi: 10.1172/JCI123955. Print 2019 May 1.
3
The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors.自然杀伤细胞介导的对自体树突状细胞的杀伤作用局限于表达CD94/NKG2A但缺乏抑制性杀伤细胞免疫球蛋白样受体的细胞亚群。
Eur J Immunol. 2003 Jun;33(6):1657-66. doi: 10.1002/eji.200323986.
4
Expression of p58.2 or CD94/NKG2A inhibitory receptors in an NK-like cell line, YTINDY, leads to HLA Class I-mediated inhibition of cytotoxicity in the p58.2- but not the CD94/NKG2A-expressing transfectant.在一种自然杀伤样细胞系YTINDY中，p58.2或CD94/NKG2A抑制性受体的表达导致HLA I类分子介导的细胞毒性抑制，这种抑制作用在表达p58.2的转染细胞中存在，而在表达CD94/NKG2A的转染细胞中不存在。
Cell Immunol. 2002 Sep;219(1):57-70. doi: 10.1016/s0008-8749(02)00578-6.
5
Direct binding of purified HLA class I antigens by soluble NKG2/CD94 C-type lectins from natural killer cells.来自自然杀伤细胞的可溶性NKG2/CD94 C型凝集素与纯化的HLA I类抗原的直接结合。
Scand J Immunol. 1999 May;49(5):459-65. doi: 10.1046/j.1365-3083.1999.00566.x.
6
HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C.人类白细胞抗原E（HLA-E）与自然杀伤细胞受体CD94/NKG2A、B及C相结合。
Nature. 1998 Feb 19;391(6669):795-9. doi: 10.1038/35869.
7
Increased frequency of human leukocyte antigen-E inhibitory receptor CD94/NKG2A-expressing peritoneal natural killer cells in patients with endometriosis.子宫内膜异位症患者中表达人类白细胞抗原-E抑制性受体CD94/NKG2A的腹膜自然杀伤细胞频率增加。
Fertil Steril. 2008 May;89(5 Suppl):1490-6. doi: 10.1016/j.fertnstert.2007.05.018. Epub 2007 Aug 13.
8
The inhibitory NK cell receptor CD94/NKG2A and the activating receptor CD94/NKG2C bind the top of HLA-E through mostly shared but partly distinct sets of HLA-E residues.抑制性自然杀伤细胞受体CD94/NKG2A和激活性受体CD94/NKG2C通过大部分共享但部分不同的HLA-E残基集合与HLA-E的顶部结合。
Eur J Immunol. 2004 Jan;34(1):81-90. doi: 10.1002/eji.200324432.
9
NK cell CD94/NKG2A inhibitory receptors are internalized and recycle independently of inhibitory signaling processes.自然杀伤细胞的CD94/NKG2A抑制性受体被内化并独立于抑制信号传导过程进行循环利用。
J Immunol. 2002 Dec 1;169(11):6102-11. doi: 10.4049/jimmunol.169.11.6102.
10
Expression patterns of lectin-like natural killer receptors, inhibitory CD94/NKG2A, and activating CD94/NKG2C on decidual CD56bright natural killer cells differ from those on peripheral CD56dim natural killer cells.蜕膜CD56bright自然杀伤细胞上凝集素样自然杀伤受体、抑制性CD94/NKG2A和激活性CD94/NKG2C的表达模式与外周CD56dim自然杀伤细胞上的不同。
J Reprod Immunol. 2006 Jun;70(1-2):33-42. doi: 10.1016/j.jri.2005.12.008. Epub 2006 Feb 20.
引用本文的文献
1
Polygenic polymorphism is associated with NKG2A repertoire and influences lymphocyte phenotype and function.多基因多态性与 NKG2A 库有关，并影响淋巴细胞表型和功能。
Blood Adv. 2024 Oct 22;8(20):5382-5399. doi: 10.1182/bloodadvances.2024013508.
2
Adoptive NK Cell Therapy - a Beacon of Hope in Multiple Myeloma Treatment.过继性自然杀伤细胞疗法——多发性骨髓瘤治疗中的希望之光。
Front Oncol. 2023 Nov 3;13:1275076. doi: 10.3389/fonc.2023.1275076. eCollection 2023.
3
All-Atom Simulations Reveal the Intricacies of Signal Transduction upon Binding of the HLA-E Ligand to the Transmembrane Inhibitory CD94/NKG2A Receptor.全原子模拟揭示 HLA-E 配体与跨膜抑制性 CD94/NKG2A 受体结合后信号转导的复杂性。
J Chem Inf Model. 2023 Jun 12;63(11):3486-3499. doi: 10.1021/acs.jcim.3c00249. Epub 2023 May 19.
4
Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines.莫纳利珠单抗的疗效与头颈部鳞状癌细胞系中的HLA-E表面表达和自然杀伤细胞活性相关。
J Cancer Res Clin Oncol. 2023 Aug;149(9):5705-5715. doi: 10.1007/s00432-022-04532-x. Epub 2022 Dec 22.
5
NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer.NKG2A 和 HLA-E 定义了膀胱癌中的另一种免疫检查点轴。
Cancer Cell. 2022 Sep 12;40(9):1027-1043.e9. doi: 10.1016/j.ccell.2022.08.005.
6
CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy.用于癌症免疫治疗的人类原代自然杀伤细胞和T细胞的CRISPR基因编辑
Front Oncol. 2022 Apr 5;12:834002. doi: 10.3389/fonc.2022.834002. eCollection 2022.
7
Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.针对自然杀伤细胞检查点受体或分子的癌症免疫治疗。
Front Immunol. 2020 Jun 23;11:1295. doi: 10.3389/fimmu.2020.01295. eCollection 2020.
8
The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy.自然杀伤细胞检查点在癌症免疫治疗中作为有前途的治疗靶点的兴起。
Front Immunol. 2019 Oct 17;10:2354. doi: 10.3389/fimmu.2019.02354. eCollection 2019.
9
Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer.自然杀伤沉默杀手：基于自然杀伤细胞的卵巢癌免疫疗法。
Front Immunol. 2019 Aug 9;10:1782. doi: 10.3389/fimmu.2019.01782. eCollection 2019.
本文引用的文献
1
Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells.阻断抑制性受体 NKG2A 的表达可克服肿瘤对 NK 细胞的抵抗。
J Clin Invest. 2019 Mar 12;129(5):2094-2106. doi: 10.1172/JCI123955. Print 2019 May 1.
2
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.抗 NKG2A mAb 是一种检查点抑制剂，通过释放 T 细胞和 NK 细胞来促进抗肿瘤免疫。
Cell. 2018 Dec 13;175(7):1731-1743.e13. doi: 10.1016/j.cell.2018.10.014. Epub 2018 Nov 29.
3
NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines.NKG2A 阻断增强癌症疫苗诱导的 CD8+T 细胞免疫。
Cell. 2018 Dec 13;175(7):1744-1755.e15. doi: 10.1016/j.cell.2018.10.028. Epub 2018 Nov 29.
4
Redefining Memory: Building the Case for Adaptive NK Cells.重新定义记忆：为适应性自然杀伤细胞提供依据
J Virol. 2017 Sep 27;91(20). doi: 10.1128/JVI.00169-17. Print 2017 Oct 15.
5
HLA-E expression and its clinical relevance in human renal cell carcinoma.HLA-E在人肾细胞癌中的表达及其临床意义
Oncotarget. 2016 Oct 11;7(41):67360-67372. doi: 10.18632/oncotarget.11744.
6
Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis.浆液性卵巢癌中非经典 HLA-I 类分子的表达：与 HLA 基因型、肿瘤浸润免疫细胞及预后的相关性
Oncoimmunology. 2015 Jul 25;5(1):e1052213. doi: 10.1080/2162402X.2015.1052213. eCollection 2016.
7
The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma.在非小细胞肺癌中，基质CD8 +肿瘤浸润性T细胞的阳性预后作用受到HLA-E表达的抑制。
Oncotarget. 2016 Jan 19;7(3):3477-88. doi: 10.18632/oncotarget.6506.
8
CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT.CD56 低表达 CD57+NKG2C+ 自然杀伤细胞扩增与减低强度造血干细胞移植后白血病复发率降低相关。
Leukemia. 2016 Feb;30(2):456-63. doi: 10.1038/leu.2015.260. Epub 2015 Sep 29.
9
The adaptor protein Crk controls activation and inhibition of natural killer cells.衔接蛋白 Crk 控制自然杀伤细胞的激活和抑制。
Immunity. 2012 Apr 20;36(4):600-11. doi: 10.1016/j.immuni.2012.03.007. Epub 2012 Mar 29.
10
HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8⁺ T lymphocytes.妇科肿瘤的 HLA-E 表达抑制肿瘤浸润的 CD8⁺ T 淋巴细胞。
Proc Natl Acad Sci U S A. 2011 Jun 28;108(26):10656-61. doi: 10.1073/pnas.1100354108. Epub 2011 Jun 13.
Zotero 插件